Efficacy and Safety of Growth Hormone Treatment in Children with Hypochondroplasia: Comparison with an Historical Cohort

Background/Aims: Hypochondroplasia (HCH) is a skeletal dysplasia characterized by disproportionate short stature. The aims of the study are to evaluate efficacy and safety of recombinant human growth hormone (r-hGH) therapy in HCH children, when compared with a historical cohort of untreated HCH children. Methods: Nineteen HCH patients with an initial height standard deviation score (SDS) ≤-2 and a mean age of 9.3 ± 3.1 years were treated with a mean r-hGH dose of 0.053 mg/kg/day over 3 years. Growth charts were derived from the historical cohort (n = 40). Results: Height gain in the treated population was +0.62 ± 0.81 SDS greater than in the general population, and +1.39 ± 0.9 SDS greater than in the historical untreated HCH cohort (mean gain of 7.4 ± 6.6 cm gain). A negative correlation between height gain and age at treatment initiation was reported (p = 0.04). There was no significant difference in response between patients with fibroblast growth factor receptor 3 mutations and those without. No treatment-related serious adverse events were reported. Conclusions: r-hGH treatment is well tolerated and effective in improving growth in HCH patients, particularly when started early. The treatment effect varies greatly and must be evaluated for each patient during treatment to determine the value of continued therapy.

[1]  F. Prodam,et al.  Effects of Growth Hormone (GH) Therapy Withdrawal on Glucose Metabolism in Not Confirmed GH Deficient Adolescents at Final Height , 2014, PloS one.

[2]  P. Cohen,et al.  Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations , 2014, Clinical endocrinology.

[3]  G. Rappold,et al.  GH treatment to final height produces similar height gains in patients with SHOX deficiency and Turner syndrome: results of a multicenter trial. , 2013, The Journal of clinical endocrinology and metabolism.

[4]  P. Bougnères,et al.  A pilot study of discontinuous, insulin-like growth factor 1-dosing growth hormone treatment in young children with FGFR3 N540K-mutated hypochondroplasia. , 2012, The Journal of pediatrics.

[5]  P. Chatelain,et al.  Optimization of Growth Hormone Dosing in Children Born Small for Gestational Age: An Open-Label, Randomized Study of Children during the Fourth Year of Therapy , 2012, Hormone Research in Paediatrics.

[6]  W. Wilcox,et al.  Sixteen years and counting: The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias , 2012, Human mutation.

[7]  M. Dattani,et al.  Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochodroplasia due to FGFR3 mutations. , 2009, The Journal of clinical endocrinology and metabolism.

[8]  G. Binder,et al.  Height Gains in Response to Growth Hormone Treatment to Final Height Are Similar in Patients with SHOX Deficiency and Turner Syndrome , 2009, Hormone Research in Paediatrics.

[9]  I. Kaitila,et al.  Growth hormone treatment in 35 prepubertal children with achondroplasia: A five‐year dose‐response trial , 2005, Acta paediatrica.

[10]  J M Wit,et al.  Nationwide age references for sitting height, leg length, and sitting height/height ratio, and their diagnostic value for disproportionate growth disorders , 2005, Archives of Disease in Childhood.

[11]  S. Kurtoğlu,et al.  Homeostasis Model Assessment Is More Reliable Than the Fasting Glucose/Insulin Ratio and Quantitative Insulin Sensitivity Check Index for Assessing Insulin Resistance Among Obese Children and Adolescents , 2005, Pediatrics.

[12]  D. Stephure.  Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. , 2005, The Journal of clinical endocrinology and metabolism.

[13]  T. Hertel,et al.  Skeletal Dysplasia, Growth Hormone Treatment and Body Proportion: Comparison with Other Syndromic and Non-Syndromic Short Children , 2003, Hormone Research in Paediatrics.

[14]  Toshiaki Tanaka,et al.  The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. , 2003, Endocrine journal.

[15]  D. Matthews,et al.  The assessment of insulin resistance in man , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[16]  J. Dumanski,et al.  Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia , 2000, Acta paediatrica.

[17]  G. Pinto,et al.  The use of insulin‐like growth factor 1 reference values for the diagnosis of growth hormone deficiency in prepubertal children , 2000, Clinical endocrinology.

[18]  T. Stijnen,et al.  Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. , 2000, The Journal of clinical endocrinology and metabolism.

[19]  W. Greulich,et al.  Radiographic Atlas of Skeletal Development of the Hand and Wrist , 1999 .

[20]  U. Ramaswami,et al.  Growth hormone therapy in hypochondroplasia , 1999, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[21]  S. Kanzaki,et al.  Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. , 1998, European journal of endocrinology.

[22]  M. Maghnie,et al.  Comparison of clinical-radiological and molecular findings in hypochondroplasia. , 1998, American journal of medical genetics.

[23]  D. Rimoin,et al.  Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. , 1996, The Journal of clinical endocrinology and metabolism.

[24]  J. Weissenbach,et al.  Clinical and genetic heterogeneity of hypochondroplasia. , 1996, Journal of medical genetics.

[25]  A. Munnich,et al.  Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. , 1996, American journal of medical genetics.

[26]  L. Key,et al.  Response to growth hormone in children with chondrodysplasia. , 1996, The Journal of pediatrics.

[27]  P. Hindmarsh,et al.  Growth characteristics and response to growth hormone therapy in patients with hypochondroplasia: genetic linkage of the insulin‐like growth factor I gene at chromosome 12q23 to the disease in a subgroup of these patients , 1991, Clinical endocrinology.

[28]  P. Hindmarsh,et al.  Growth and Growth Hormone Therapy in Hypochondroplasia , 1990, Acta paediatrica Scandinavica.

[29]  S. Garn,et al.  Radiographic Atlas of Skeletal Development of the Hand and Wrist. , 1959 .

[30]  G. Werther,et al.  Skeletal Dysplasias: Response to Growth Hormone Therapy , 1996, Journal of pediatric endocrinology & metabolism : JPEM.

[31]  I. Kaitila,et al.  A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia , 1995, Nature Genetics.

[32]  P. Hindmarsh,et al.  Growth of children with hypochondroplasia treated with growth hormone for up to three years. , 1991, Hormone research.

[33]  T J Cole,et al.  Body Mass Index variations: centiles from birth to 87 years. , 1991, European journal of clinical nutrition.